Sex steroid optimization across the lifespan has implications for both psychiatric symptoms and cognitive longevity. Estrogen in women — particularly the timing of menopausal hormone therapy — has accumulated evidence relevant to cognitive trajectory; testosterone in men with hypogonadism affects mood, cognition, and possibly broader longevity outcomes. The clinical conversations have evolved substantially with newer evidence; the prescribing landscape requires nuanced engagement with patients about benefits, risks, and individualized decisions.
The WHI legacy and timing hypothesis. The 2002 Women's Health Initiative initial publication produced widespread reduction in menopausal hormone therapy prescribing due to cardiovascular and cancer concerns. Subsequent reanalysis and additional trials have substantially modified the picture — timing matters (initiation in early menopause is different from initiation 10+ years post-menopause), formulation matters (transdermal estrogen better cardiovascular profile than oral), individual risk factors matter. The current consensus supports hormone therapy for many symptomatic perimenopausal and early postmenopausal women with appropriate risk assessment.
Estrogen and cognitive trajectory. Observational data and some randomized trials suggest that estrogen initiated in the early menopausal window (within 5-10 years of menopause) may have cognitive-protective effects; estrogen initiated decades after menopause does not show this benefit and may carry risk. The "critical window" hypothesis informs current practice. The KEEPS and ELITE trials, while not definitive, support the timing-matters frame. The decision for individual patients balances symptom severity, cardiovascular and cancer risk factors, and patient preference.
Testosterone and male cognitive longevity. Hypogonadism (clinically and biochemically confirmed low testosterone with symptoms) treatment in men has evidence for mood, energy, libido, body composition, and possibly cognitive outcomes. The TRAVERSE trial provided cardiovascular safety data; the broader picture supports treatment in confirmed hypogonadism with appropriate monitoring. The treatment of "low normal" testosterone in men without clear hypogonadism is more controversial; the longevity-medicine practice has expanded into this territory ahead of robust evidence.
The bioidentical hormone replacement (BHRT) landscape. Compounded BHRT preparations are widely used; the formulations vary substantially in quality and dosing. Pharmaceutical-grade bioidentical hormones (FDA-approved transdermal estradiol, micronized progesterone) have evidence base; compounded products without FDA oversight are more variable. The clinical conversation includes the distinction between FDA-approved bioidentical products and compounded preparations, with informed consent about evidence quality.
The clinical recommendations and longitudinal management. For perimenopausal and early postmenopausal women with significant symptoms: hormone therapy is reasonable consideration with individualized risk assessment. For men with confirmed hypogonadism: testosterone replacement is reasonable with appropriate monitoring (hemoglobin, PSA, cardiovascular). For the broader "hormonal optimization" or anti-aging hormone use in patients without clear deficiency: the evidence is limited and the practice runs ahead of data. The longevity-psychiatry frame engages hormonal optimization where evidence supports it, coordinates with appropriate prescribing clinicians, and remains evidence-informed about the limits of what is established. The discipline is to engage sex steroid considerations honestly across the lifespan, coordinate with prescribing clinicians (PCP, gynecology, endocrinology, urology), and integrate hormonal interventions into the broader cognitive optimization framework.